|
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors Clinical research trials and A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors. A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors clinical trial. Subjects often receive the most expert healthcare possible for their A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors  A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
For Condition: Brain Neoplasms,Glioma,Medulloblastoma
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the maximum tolerated dose of RMP-7 in children with refractory brain tumors.
Details: The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the maximum tolerated dose of RMP-7 in children with refractory brain tumors.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: Histologically confirmed brain tumor including but not limited to the following: Anaplastic astrocytoma, Glioblastoma multiforme, Low-grade glioma, Ependymoma, Medulloblastoma, Pineal tumors, Chiasmal glioma, Craniopharyngioma, Brain stem glioma (requirement for histologic diagnosis may be waived). Disease refractory to standard therapy or no standard chemotherapy exists and ineligible for potential curative surgery or radiotherapy. Measurable or evaluable disease on radiographic studies with evidence of progression on prior chemotherapy or radiotherapy or persistent disease after surgery. PRIOR/CURRENT THERAPY: See Disease Characteristics At least 6 months since carboplatin. At least 3 weeks since myelosuppressive therapy. Patients who received stem cell or bone marrow rescue after nitrosourea therapy are eligible after 3 weeks if they have recovered from hematologic toxicities of their prior therapy. Concurrent steroids allowed if dose stable for at least 2 weeks prior to entry. Recovered from toxic effects of any prior therapy. PATIENT CHARACTERISTICS: Age: 21 and under. Performance status: ECOG 0-2. Life expectancy: At least 8 weeks. HEMATOLOGIC: Absolute granulocyte count greater than 1,500/mm(3). Platelet count greater than 100,000/mm(3) (at least 75,000/mm(3) in patients with prior bone marrow transplantation or craniospinal irradiation). Hemoglobin greater than 8.0 g/dL. HEPATIC: Bilirubin no greater than 2 times normal. ALT no greater than 2 times normal. RENAL: Creatinine within normal limits for age as follows: Age (in years) -- Creatinine (in mg/dL): Younger than 5 -- no greater than 1.2; 5-10 -- no greater than 1.5; 10-15 -- no greater than 1.8; Older than 15 -- no greater than 2.4. OTHER: No significant systemic illness. No pregnant or nursing women. Negative pregnancy test required of fertile women. Effective contraception required of fertile patients. Durable power of attorney required of all patients 18-21 years of age.
Total Enrollment: 30
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960068; 96-C-0068
Study Start Date: April 24, 1996
Record last reviewed: February 10, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001502
Other Medulloblastoma Studies:
1. A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
2. Natural History of Patients with Brain and Spinal Cord Tumors
3. A Phase II Trial of Intravenous Cereport ® (Registered Trademark) (RMP-7) and Carboplatin in Childhood Brain Tumors
Related Studies:
Other Medulloblastoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
|
|
|
|
|
|
|
|
